Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis

Minnema, M. C., Dispenzieri, A., Merlini, G., Comenzo, R. L., Kastritis, E., Wechalekar, A. D., Grogan, M., Witteles, R., Ruberg, F. L., Maurer, M. S., Tran, N., Qin, X., Vasey, S. Y., Weiss, B. M., Vermeulen, J., & Jaccard, A. (2022). Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis. JACC: CardioOncology, 4(4), 474–487. https://doi.org/10.1016/j.jaccao.2022.08.011
Authors:
Monique C. Minnema
Angela Dispenzieri
Giampaolo Merlini
Raymond L. Comenzo
Efstathios Kastritis
Ashutosh D. Wechalekar
Martha Grogan
Ronald Witteles
Frederick L. Ruberg
Matthew J. Maurer
Namphuong Tran
Xiang Qin
Sandra Y. Vasey
Brendan M. Weiss
Jessica Vermeulen
Arnaud Jaccard
Affiliated Authors:
Matthew J. Maurer
Columbia Affiliation:
Subjects:
Molecular Mechanisms of Amyloidosis (OpenAlex Topic)
Epidemiology and Pathogenesis of Pneumocystis Pneumonia (OpenAlex Topic)
Epidemiology and Management of Neuroendocrine Tumors (OpenAlex Topic)
Author Keywords:
daratumumab
mayo staging system
ae, adverse event
al, amyloid light chain
cr, complete response
d-vcd, daratumumab, bortezomib, cyclophosphamide, and dexamethasone
efs, event-free survival
flc, free light chain
nt-probnp, n-terminal pro–brain natriuretic peptide
nyha, new york heart association
pfs, progression-free survival
sae, serious adverse event
vcd, bortezomib, cyclophosphamide, and dexamethasone
hs-ctnt, high-sensitivity cardiac troponin t
elink
Publication Type:
Article
Unique ID:
10.1016/j.jaccao.2022.08.011
PMID:
36444227
DOI:
10.1016/j.jaccao.2022.08.011
Journal:
JACC: CardioOncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: